Overview
- Tilray reported adjusted EPS of $0.01 versus an expected $0.20 loss and revenue of $217.51 million versus $210.95 million consensus.
- Shares climbed roughly 7% in extended and premarket trading following the results.
- Adjusted EBITDA reached $8.4 million, and the company reaffirmed full‑year fiscal 2026 adjusted EBITDA guidance of $62 million to $72 million.
- Performance was led by international medical cannabis, Canadian adult‑use and distribution, with Tilray Pharma posting its best quarter, and cash totaled $291.6 million with a $27.4 million net cash position.
- CEO Irwin D. Simon emphasized Tilray Medical U.S. with plans to initiate FDA trials and leverage existing medical platforms, as investors track potential federal rescheduling that could improve tax treatment.